MONTRÉAL, le 31 mai 2022 /CNW/ - Innodem Neurosciences, leader de la santé numérique, assurant la convergence des neurosciences, de la pharmaceutique et de l'intelligence artificielle, est fière d'annoncer que sa nouvelle technologie mobile de suivi oculaire pour les...
MONTRÉAL, 5 octobre 2021 /PRNewswire/ -- Innodem Neurosciences a annoncé aujourd'hui qu'elle a conclu un accord de partenariat de plusieurs années avec Novartis Pharmaceuticals Canada Inc. (Novartis) afin de conduire une étude clinique révolutionnaire pour aider les...
CENTECH, a Montreal-based technology incubator, announced earlier that it has selected a company founded by Dr. Etienne de Villers-Sidani for its Propulsion Program, which helps the most innovative start-ups move from the initial development phase to commercializing...
Dr. de Villers-Sidani was amongst the three McGill researchers presented their work to the World Economic Forum’s (WEF) Annual Meeting of the New Champions (a.k.a. “Summer Davos”) on September 18, in Tianjin, China. It’s the foremost global summit on innovation,...
Montreal-based Innodem Neurosciences has received $1 million from angel, banking, and government entities to begin commercializing Pigio™, its first mobile app. Pigio™ uses AI-powered mobile software technology to allow paralyzed or intubated patients to communicate...
Patients who have lost the use of speech will soon be able to communicate with their eyes thanks to a mobile application developed in Quebec. Called Pigio™, the application will allow communication with the eyes, which act as a cursor on a digital screen. "You have...
Innodem Neurosciences, société montréalaise, clôture une ronde de Série A Morningside Ventures pour soutenir le développement et la commercialisation de sa technologie brevetée d’analyse des biomarqueurs des maladies neurodégénératives telles que la sclérose en...